Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 T-cell receptor mimic antibody
- Development stage
- Preclinical
- Lead developer
- Biocytogen
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NY-ESO-1 T-cell receptor mimic antibody is a fully human monoclonal antibody developed by Biocytogen using its proprietary RenMab mouse platform and TCR-mimic (TCRm) technology. The antibody is engineered to recognize the intracellular cancer-testis antigen NY-ESO-1 (specifically the 157-165 peptide SLLMWITQC) when presented on the cell surface by the HLA-A*02 MHC class I molecule. By mimicking the specificity of a T-cell receptor but with the high affinity characteristic of a monoclonal antibody (nanomolar range), it overcomes the low-affinity limitations of natural TCRs. This candidate is primarily intended for use in cell therapy, such as TCRm-engineered T cells (TCRm-T), to target and eliminate NY-ESO-1-expressing tumor cells in HLA-A02-positive patients. It has demonstrated potent and specific anti-tumor activity in preclinical models of synovial sarcoma, melanoma, and neuroblastoma.
- Other names
- NY-ESO-1 TCRm antibodyNY-ESO1 TCRm antibodyNY-ESO 1 TCRm antibodyBiocytogen NY-ESO-1 TCRm
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on NY-ESO-1 T-cell receptor mimic antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 T-cell receptor mimic antibody.